Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Celgene is on a course to transition from a company centered mainly on the multiple myeloma blockbuster Revlimid to a diversified biotech over the next five years. That’s the strategy management laid out for investors during an R&D day in New York April 8.

You may also be interested in...



Celgene/Agios Team Up In Long-Term Cancer Metabolism Pact

Agios will receive $130 million upfront, while Celgene gains the option to develop any drugs resulting from the biotech's cancer metabolism research platform for an undisclosed period of time.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals

Product

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel